NCT00492427已完成3 期
Correction and Maintenance Study of Subcutaneous Injections of R744 to Predialysis Patients ( Phase III, Comparative Study in Comparison With Epoetin Beta)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 187
- 试验地点
- 6
- 主要终点
- Rate of patients who maintain mean Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL
研究概览
简要总结
This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of subcutaneous R744 in renal anemia patients on Predialysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients whose serum creatinine level has been ≥ 2.0 mg/dL or creatinine clearance has been ≤ 30 mL /min at any one time point within 12 weeks before registration
- •Patients aged ≥ 20 years at the time of obtaining consent
- •Patients who have been not receiving a rHuEPO preparation at least 16 weeks before registration
- •Patients whose value of Hb concentrations determined the nearest week before registration has been < 10.0 g/dL
- •Patients whose transferrin saturation has been ≥ 20 % or ferritin has been ≥ 100ng/mL at any time point within 8 weeks before registration
排除标准
- •Patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12 weeks before registration)
- •Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function classification)
- •Female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug
- •Patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction)
- •Patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom)
- •Patients hypersensitive to a rHuEPO preparation
- •Patients with malignant tumor (including hemic malignant tumor), severe infection, systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.), hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage
- •Patients who have received an anabolic hormone preparation, testosterone enanthate or mepitiostane within 12 weeks before registration
- •Patients who have received another investigational drug within 12 weeks before registration
- •Patients who have received R744 before registration
- •Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before registration
- •Patients who have received erythrocyte transfusion within 16 weeks before registration
- •Patients for whom a surgical operation accompanied by marked bleeding is planned during the study period
- •In addition, patients who are judged as ineligible to participate in this study by the investigator or subinvestigator
研究组 & 干预措施
2
Active Comparator
干预措施: Epoetin beta (Drug)
1
Experimental
干预措施: R744 (Drug)
结局指标
主要结局
Rate of patients who maintain mean Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL
时间窗: 26 weeks
次要结局
- Variation of QOL(26 weeks)
- Mean Hb concentration for term of evaluation(26 weeks)
- The ratio of patients whose Hb concentration reach ≥ 10.0g/dL and increasing amount of Hb concentration reach ≥ 1.0g/dL(26 weeks)
- Time required for reaching Hb concentration of ≥ 10.0 g/dL and reaching increasing amount of Hb concentration of ≥ 1.0g/dL(26 weeks)
- Slope of regression line of Hb concentration per week(26 weeks)
- Adverse events(26 weeks)
- Laboratory measurements(26 weeks)
- Vital signs, standard 12-lead ECG(26 weeks)
- Anti-R744 antibody titer(26 weeks)
- Anti-Epoetin beta antibody titer(26 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Clinical Study of R744 to Hemodialysis PatientsHemodialysis PatientsNCT00491868Chugai Pharmaceutical134
已完成
3 期
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With EpoetinChronic Kidney DiseaseChronic Renal FailureNCT01473420Pfizer320
已完成
不适用
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving ChemotherapyAnemiaNCT01809314Hoffmann-La Roche1,167
进行中（未招募）
2 期
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Squamous Cell CarcinomaNCT06041802Merck Sharp & Dohme LLC19
未知
3 期
R744 clinical traialJPRN-jRCT2080220983Chugai Pharmaceutical Co., Ltd.70